The Trump administration disclosed Monday that it had opened an investigation into the effects on national security of importing certain pharmaceuticals, a move widely seen as the prelude to initiating tariffs on prescription drugs. The Department of Commerce in a Federal Register notice said the probe, known as a Section 232 investigation, began April 1, the day…
Source link
2025-04-14
